NEW YORK (GenomeWeb News) – CombiMatrix today announced a contract with FedMed for coverage of the Irvine, Calif.-based firm's diagnostic laboratory services.

FedMed is a national provider network and healthcare financial services firm with a preferred provider network of more than 550,000 physicians, 4,000 hospitals, and 60,000 ancillary care providers in the US. More than 40 million people have access to the network, CombiMatrix said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.